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Introduction
Electroporation is the application of elec-
tric pulses to cells in vitro or tumours in 
vivo. It is effective in facilitating the trans-
port of different molecules with otherwise 
hampered transport across the plasma 
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Background. Electrochemotherapy is a local treatment combining application of electric pulses and chemo-
therapy. Two chemotherapeutic drugs, bleomycin and cisplatin, have proved to be effective in electrochemo-
therapy. The effectiveness of electrochemotherapy was demonstrated in the treatment of various cutaneous 
and subcutaneous tumours in cancer patients. Only a few preclinical studies were performed in colorectal 
carcinoma, mostly using bleomycin. Our aim was to evaluate the sensitivity of the murine colorectal carci-
noma cell line CMT-93 to electrochemotherapy with bleomycin and cisplatin for potential use in preclinical 
and clinical studies.
Methods. CMT-93 cells were exposed to either the chemotherapeutic drug alone or electrochemotherapy. 
A clonogenic assay was used to determine cell survival after treatment. Apoptosis was measured by cas-
pase-3/7 activity, necrosis by changes in cell morphology and cell viability by the MTS assay 16 hours 
after electrochemotherapy. 
Results. Cells treated with electrochemotherapy were 500-fold more sensitive to bleomycin and 2.8-fold 
more sensitive to cisplatin compared to cells treated with the drugs alone. At the highest concentrations, a 
significant reduction in cell viability, increase in caspase-3/7 activity and necrotic cells were observed after 
electrochemotherapy.
Conclusions. Exposure of cells to electric pulses enhanced cytotoxicity of both bleomycin and cisplatin. 
Reduced cell viability was due to apoptotic and necrotic cell death. Furthermore, electrochemotherapy with 
bleomycin was more cytotoxic than electrochemotherapy with cisplatin in this colorectal carcinoma cell line.
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membrane, including chemotherapeutic 
drugs.1,2 Electroporation can be used in 
combination with chemotherapy (electro-
chemotherapy) or gene therapy (electro-
gene therapy) to increase the uptake of 
chemotherapeutic drugs, or nucleic acids, 
respectively. So far, two chemotherapeutic 
drugs have proved to be effective in elec-
trochemotherapy, bleomycin (BLM) and 
cisplatin (CDDP). Electroporation with 
BLM or CDDP significantly enhances the 
cytotoxicity of these drugs in different tu-
mour cell line s, also of CDDP-resistant cell 
lines and solid experimental tumours.3-6 
Furthermore, its effectiveness was demon-
strated in the treatment of various cutane-
ous and subcutaneous tumours of various 
malignancies.7,8 
Colorectal carcinoma is one of the most 
common cancers worldwide, and its inci-
dence is increasing. Traditional treatment 
modalities for colorectal carcinoma are 
surgery, chemotherapy and/or radiation. 
However, not all patients can undergo sur-
gery due to severe complications, such as 
chronic heart failure, chronic renal failure, 
and chronic obstructive pulmonary disea-
ses.9 Chemotherapy can be used for these 
patients, yet its effectiveness is limited by 
side effects. However, if further progress in 
reducing colorectal carcinoma mortality is 
to be accomplished, new treatment strate-
gies are needed.
Electrochemotherapy could provide an 
innovative therapeutic approach for the 
treatment of colorectal carcinoma. The ma-
jority of studies evaluating the antitumour 
effect of electrochemotherapy concentrated 
on cutaneous and subcutaneous tumours of 
various histology, and only a few on colorec-
tal carcinoma.9,10 Therefore, the aim of our 
study was to evaluate the in vitro sensitivity 
of the murine colorectal carcinoma cell line 
CMT-93 to electrochemotherapy with BLM 
and CDDP for potential use in preclinical 
and clinical studies on colorectal carcinoma.
Materials and methods
Cell line
Murine rectum carcinoma cells CMT-93 
(American Type Culture Collection, USA) 
were grown in Dulbecco’s Modified Eagle 
Medium (DMEM) with Glutamax (Gibco, 
Invitrogen, Paisley, UK), supplemented with 
10% foetal calf serum (FCS) (Invitrogen, 
Paisley, UK) and gentamicin (30 µg/mL) 
(Gibco, Invitrogen, Paisley, UK). Cells were 
routinely subcultured twice a week and in-
cubated in an atmosphere with 5% CO2 at 
37°C.
Drugs
BLM (Blenamax) was obtained from Phar-
machemie BV (Haarlem, the Netherlands) 
as a crystalline powder. BLM was dissolved 
in saline (0.9% NaCl) at a concentration 1.5 
mg/mL. CDDP (Cisplatyl) was obtained 
from Aventis (Paris, France) as a crystalline 
powder. CDDP was dissolved in sterile H2O 
at a concentration of 1 mg/mL (3.3 mM). For 
each experiment, a fresh solution of BLM or 
CDDP was prepared. The final concentra-
tions of both BLM and CDDP were prepared 
in DMEM. BLM concentrations of 0.00001 
µM to 1 µM and CDDP concentrations of 
6.7 µM to 266.6 µM were used in the experi-
ments.
Electrochemotherapy protocol
Confluent cell cultures were trypsinized, 
washed in DMEM with FCS for trypsin in-
activation and once in electroporation buff-
er (125 mM saccharose; 10 mM K2HPO4; 2.5 
mM KH2PO4; 2 mM MgCl2·6H20) at 4°C. 
The final cell suspension was prepared in 
electroporation buffer at 4°C and a concen-
tration of 22 x 106 cells/mL. For the clono-
genic assay, 90 µL of final cell suspension 
was mixed with 10 µL of BLM or CDDP 
solution at different concentrations. 50 µL 
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of the mixture (1 x 106 cells) were placed 
between two parallel electrodes with a 2 
mm gap in-between and subjected to eight 
square wave electric pulses with electric 
field intensity 1300 V/cm, pulse duration 
100 µs and frequency 1 Hz. Electric pulses 
were generated by an in-house build electro-
porator (University of Ljubljana, Faculty of 
Electrical Engineering, Ljubljana, Slovenia). 
Another 50 µL of the mixture (1 x 106 cells) 
served as a control of CDDP treatment 
alone. After electroporation, cells were in-
cubated at room temperature for 5 min, di-
luted in 2 mL of growth medium and then 
plated for clonogenic, caspase-3/7 activity, 
cell viability assays, and Giemsa staining.
Clonogenic assay
CMT-93 cells were plated at a concentra-
tion of 300 cells/dish for exposure to BLM 
alone and 1200 cells/dish for combina-
tion of electroporation and BLM, whereas 
600 cells/dish were plated for both CDDP 
alone and a combination of electroporation 
and CDDP. After 9 and 10 days (BLM and 
CDDP, respectively) colonies were fixed, 
stained with crystal violet and counted. The 
survival curve for the electrochemotherapy-
treated cells was normalised for the cytotox-
icity of electric pulses treatment alone. The 
inhibitory concentration of each treatment 
that reduced cell survival to 50% (IC50) was 
determined graphically in each experiment. 
The experiment was repeated three times in 
triplicates for both BLM and CDDP.  
Apoptosis 
Apoptosis was measured by caspase-3/7 ac-
tivity that was evaluated using the Caspase-
Glo 3/7 Assay (Promega, Madison, USA) 
according to the manufacturer’s instruc-
tions. After the electrochemotherapy proto-
col, CMT-93 cells (1.5 x 104 cells/well) were 
seeded in a 96-well plate (TPP, Trasadingen, 
Switzerland) and incubated at 37°C. After 
16 h, a solution of Caspase-Glo 3/7 sub-
strate and buffer (ratio 20 : 1) (Promega, 
Madison, USA) was added to each well. 
Plates were further incubated at 37°C for 
2 h and luminescence was measured at 1 s 
integration time using a microplate reader 
(Tecan, Salzburg, Austria). The experi-
ment was repeated twice in quintuplicates. 
Caspase-3/7 activity was normalized to the 
number of viable cells (as determined by 
the cell viability assay). Caspase-3/7 fold 
induction was determined as the ratio be-
tween caspase-3/7 activity in treated and 
control cells.
Cell viability was evaluated using the 
CellTiter 96 Aqueous One Solution Cell 
Proliferation Assay (Promega, Madison, 
USA) according to the manufacturer’s in-
structions. After the electrochemotherapy 
protocol, CMT-93 cells (1.5 x 104 cells/
well) were seeded in a 96-well plate (TPP, 
Trasadingen, Switzerland) and incubat-
ed at 37°C. After 16 h, a solution of MTS 
with PMS (ratio 20 : 1) was added to each 
well. Plates were further incubated at 37°C 
for 2 h and absorbance was measured at 
492 nm using a microplate reader (Tecan, 
Salzburg, Austria). The experiment was re-
peated three times in quintuplicates.
Necrosis 
Necrosis was evaluated by morphological 
changes in cells stained with Giemsa. For 
Giemsa staining, CMT-93 cells (7 x 104 cells/
well) were plated in chamber slides 5 min 
after electroporation. After 18 h, the me-
dium was removed and cells were washed 
with PBS. Cells were fixed in cold metha-
nol for 20 min and then washed under run-
ning water. Extra liquid was wiped away 
and Giemsa’s azure eosin methylene blue 
solution (Merck, Darmstadt, Germany) was 
added to the slides for 20 min. After incu-
bation, slides were washed under running 
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water and air-dried. Samples were evalu-
ated under a IX51 inverted microscope 
(Olympus, Tokyo, Japan). Photographs 
were taken with a CCD camera ColorView 
III (Soft Imaging System, Münster, 
Germany).
Results
Clonogenic assay
Exposure of CMT-93 cells to electric pulses 
resulted in an increase in both BLM and 
CDDP cytotoxicity (Figure 1). Throughout 
the range of BLM and CDDP concentrations 
investigated, cells exposed to either BLM or 
CDDP and electric pulses were more sen-
sitive to the chemotherapeutics than those 
which were not exposed. The cells exposed 
to electric pulses were 2.8-fold more sen-
sitive to CDDP as determined by the IC50 
value. The cells exposed to electric pulses 
were 500-fold more sensitive to BLM as de-
termined by the IC50 value. The surviving 
fraction of cells treated with electric pulses 
alone was 0.44 ± 0.04 (data not shown).
Apoptosis after 
electrochemotherapy 
with BLM
After BLM treatment, cas-
pase-3/7 fold induction was 
significantly increased at 
1 µM BLM in comparison to 
other tested concentrations 
(p<0.05). After electroche-
motherapy with BLM, the 
caspase-3/7 fold induction 
was significantly increased 
both at 0.1 µM and 1 µM 
BLM. Interestingly, cas-
pase-3/7 fold induction was 
higher at 0.1 µM BLM; how-
ever, the difference was not 
significant (Figure 2). 
The cell viability in the 
range of tested BLM con-
centrations was decreased and it reached 
73% at the highest tested BLM concentra-
tion. In comparison to control non-treated 
cells, cell viability is significantly reduced at 
0.0001 µM BLM and higher (p<0.05). After 
electrochemotherapy with BLM, there was 
no significant difference in cell viability at 
low BLM concentrations (0.00001 µM - 0.01 
µM). However, at 0.1 µM and 1 µM BLM, 
cell viability was significantly reduced in 
comparison to other tested concentrations. 
Interestingly, there was no significant dif-
ference in cell viability between these two 
concentrations (Figure 2).
Apoptosis after electrochemotherapy 
with CDDP
After CDDP treatment, the caspase-3/7 
fold induction was significantly increased 
at 266.6 µM CDDP in comparison to oth-
er tested concentrations (p<0.05). After 
electrochemotherapy with CDDP, the cas-
pase-3/7 fold induction was significantly 
increased at 133.3 µM and 266.6 µM CDDP 
(p<0.05). Caspase-3/7 fold induction was 
Figure 1. Potentiation of  BLM and CDDP cytotoxicity in vitro by 
electroporation of CMT-93 cells. (A) Surviving fraction of CMT-93 cells 
after treatment with BLM alone or after electrochemotherapy with BLM. (B) 
Surviving fraction of CMT-93 cells after treatment with CDDP alone or after 
electrochemotherapy with CDDP. 
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significantly higher at 266.6 µM than 133.3 
µM CDDP (p<0.05) (Figure 3).
The cell viability in the range of tested 
CDDP concentrations was decreased and 
it reached 79% at the highest tested CDDP 
concentration. In comparison to control 
non-treated cells, cell viability after CDDP 
treatment was significantly reduced only 
at 133.3 µM and 266.6 µM CDDP (p<0.05). 
Interestingly, a significantly decreased cell 
viability was observed at 266.6 µM CDDP 
in comparison to other tested concentra-
tions (p<0.05), but not to 133.3 µM. After 
electrochemotherapy with CDDP, cell vi-
ability was significantly reduced at 266.6 
µM in comparison to all other tested con-
centrations (p<0.05) (Figure 3). 
Necrosis after electrochemotherapy with 
BLM or CDDP
Cells were stained with Giemsa to evaluate 
the effect of BLM or CDDP treatment or 
electrochemotherapy with BLM or CDDP 
on cell morphology, specifically to deter-
mine necrosis. CMT-93 cells displayed 
Figure 2. Cell viability (A) and caspase-3/7 fold induction (B) of CMT-93 cells after electrochemotherapy with 
BLM. Data are mean values pooled from two or three independent experiments. * p<0.05. 
Figure 3. Cell viability (A) and caspase-3/7 fold induction (B) of CMT-93 cells after electrochemotherapy with 
CDDP. Data are mean values pooled from two or three independent experiments. * p<0.05.
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typical epithelial morphology. The effect 
of electric pulses on cell morphology was 
only minor; some cells were enlarged and 
only a few cells displayed morphologi-
cal characteristics typical for apoptotic or 
necrotic cell death. However, morphologi-
cal changes progressively increased with in-
creasing BLM or CDDP concentrations and 
also after electrochemotherapy. After treat-
ment with higher BLM or CDDP concentra-
tions, changes in cell size and shape were 
observed in comparison to control non-
treated cells. Cells were enlarged, some 
were also multinucleated, and cytoplasm 
was vacuolarized. Apoptotic bodies, pikno-
sis, karyorrhexis, and karyolysis, were also 
observed in comparison to control cells in-
dicating necrotic cell death. These changes 
were more evident at higher concentrations 
of BLM or CDDP. On the other hand, after 
electrochemotherapy with BLM or CDDP 
the above-mentioned morphological chang-
es were already observed at lower BLM or 
CDDP concentrations (Figure 4).
Discussion
In this study, we demonstrated the ef-
fectiveness of electrochemotherapy with 
BLM or CDDP on the CMT-93 colorectal 
carcinoma cell line. The exposure of cells 
to electric pulses enhanced cytotoxicity of 
both BLM and CDDP. Reduced cell viabil-
ity was due to apoptotic and necrotic cell 
death. Furthermore, electrochemotherapy 
with BLM was more cytotoxic than electro-
chemotherapy with CDDP in CMT-93 color-
ectal carcinoma cells.
Our results demonstrate enhanced cy-
totoxicity of both chemotherapeutic drugs 
after electrochemotherapy. After exposure 
of the CMT-93 cell line to a combination of 
electric pulses and the chemotherapeutic 
drug, the cells were 2.8-fold more sensi-
tive to CDDP and 500-fold more sensitive 
to BLM in comparison to exposure to the 
drug alone. A similar study also tested 
susceptibility of colorectal carcinoma cell 
lines Colorectal 26 and MC38 to electroche-
motherapy. It demonstrated that these cells 
were much more sensitive to BLM cytotox-
icity. Furthermore, cytotoxicity potentia-
tion was significant only for BLM, but not 
for CDDP treatment.9 
Previously, IC50 values (Table 2) were de-
termined for different human and murine 
tumour cell lines for treatment with BLM 
or CDDP alone or in combination with 
electroporation.3,6,9,11-13 Compared to these 
studies, CMT-93 cells appear more resistant 
to CDDP then other cell lines, even after 
electroporation, although electroporation 
significantly increased sensitivity to CDDP. 
CMT-93 cells were more sensitive to BLM, 
and after electroporation, cytotoxicity was 
potentiated 500-fold. Our results are also 
in agreement with the previously reported 
fact that electroporation of cells potentiates 
BLM cytotoxicity up to several thousand-
fold, whereas CDDP cytotoxicity is potenti-
ated up to 80-fold.14
The difference between enhancement 
of BLM and CDDP cytotoxicity can be as-
Table 1. IC50 values of CMT-93 cell line treated with 
either BLM or CDDP with (+EP) or without (-EP) 
electroporation
IC50
drug - EP + EP fold increase
BLM 0.1 µM 0.0002 µM 500
CDDP 192.7 µM 68.3 µM 2.8
Table 2. The range of IC50 values of different human 
and murine tumour cell lines treated with either BLM 
or CDDP with (+EP) or without (-EP) electroporation 
IC50
drug - EP + EP
BLM 0.1 - 500 µM 0.0002 – 4.3 µM
CDDP 0.83 – 1000 µM 0.083 – 106 µM
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cribed to the uptake of the drugs and also 
intracellular action of these drugs. Namely, 
the plasma membrane limits both BLM 
and CDDP uptake in the cells, as they can-
not freely diffuse through the membrane. 
CDDP is a small inorganic molecule that 
enters the cells to some extent by passive 
diffusion and also by active transport via 
carrier molecules.15,16 However, the overall 
flux across the membrane is limited. On 
the other hand, BLM is a complex organic 
molecule, and as such cannot diffuse freely 
across the plasma membrane.17 The exact 
mechanism of its uptake is not known, 
however, involvement of receptor proteins 
on the plasma membrane is indicated.18
DNA is the main intracellular target of 
both BLM and CDDP. However, the mecha-
nism of their cytotoxicity differs. CDDP 
interacts with DNA to form DNA-protein 
and DNA-DNA crosslinks.19 On the other 
hand, BLM induces single- and double-
strand DNA breaks.20 When DNA damage, 
induced by either CDDP or BLM, exceeds 
the threshold level, cell death is triggered. 
The primary cytotoxic mechanism of DNA-
damaging antitumour drugs may be induc-
tion of apoptosis. However, other types of 
cell death can occur in cell cultures exposed 
to the same drug. Individual cell death af-
ter BLM or CDDP exposure might be de-
termined by several factors. It is depend-
ent on drug concentration, the availability 
of energy and the metabolic condition of 
the cell.15,21,22 BLM-induced DNA damage 
can trigger the apoptotic, pseudoapoptotic 
or mitotic cell death pathway. At low BLM 
concentrations, cells die of mitotic cell 
death, at intermediate BLM concentrations 
apoptosis is induced, whereas at high BLM 
concentrations, an apoptosis-like process 
takes place.20,23 Also, apoptosis, necrosis, 
and mitotic cell death have been found 
in the same population of CDDP-treated 
cells.21,24 At high CDDP concentrations 
(800 µM), cells undergo necrotic cell death 
over a few hours after treatment, whereas 
at low CDDP concentration (8 µM) cells un-
dergo apoptosis following exposure to the 
drug over several days.22
Apoptosis is a mode of cell death char-
acterized by unique morphological and bio-
A
B
C
D
E
F
Figure 4. Changes in cell morphology were determined with Giemsa staining. (A) Control non-treated CMT-93 cells. 
(B) Cells exposed to electric pulses only. (C) Cells exposed to 1 µM BLM. (D) Cells exposed to electrochemotherapy 
with 1 µM BLM. (E) Cells exposed to 266.6 µM CDDP. (F) Cells exposed to electrochemotherapy with 266.6 µM CDDP.
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chemical features. These include loss of cell-
cell contact, cell shrinkage and blebbing, 
recognition by phagocytic cells, condensa-
tion and fragmentation of the nucleus, de-
pendence on the energy supplied by ATP, 
and active protein synthesis.21,25 Apoptosis 
results from activation of the caspase fami-
ly of aspartate-specific proteases. Upstream 
caspases are activated early in the apoptotic 
process and they activate downstream cas-
pases, such as caspase-3 and -7. These cas-
pases are largely responsible for the cleav-
age of many other cellular proteins, leading 
to apoptosis.21 Measurements of caspase-3 
and caspase-7 activity can be used to detect 
apoptosis in cell cultures. 
Since caspase activation is dependant on 
metabolic activity of the cell, the cell viabili-
ty assay and caspase-3/7 activity assay were 
used to evaluate cell death pathway after 
electrochemotherapy. Cell viability and cas-
pase-3/7 activity were determined 16 hours 
after electrochemotherapy, and caspase-3/7 
activity was normalized to the number of 
viable cells. Only cells with an active me-
tabolism can produce ATP and form a cas-
pase activation complex, leading to activa-
tion of executioner caspases-3 and -7. Our 
study demonstrated decreased cell viability 
after exposure to BLM or CDDP. However, 
loss of cell viability was more prominent at 
high concentrations. Cell viability was fur-
ther decreased after electrochemotherapy. 
The effect was more pronounced after elec-
trochemotherapy with BLM than CDDP. 
Furthermore, electrochemotherapy with 
either BLM or CDDP activated caspases-3 
and -7. However, the caspase-3/7 fold in-
duction was significantly increased only 
at the highest concentrations of BLM and 
CDDP used. 
Our results suggest that at low BLM con-
centrations, cells die after a few cell cycles 
in a caspase-independent slow cell death 
process and are in agreement with already 
demonstrated results that at a BLM concen-
tration of 10 nM and below cells die slowly 
through a mitotic cell death.23 Our results 
further demonstrated that at the highest 
tested BLM concentrations (0.1 µM and 1 
µM), caspase-3/7 activation is apparent and 
this leads to the conclusion that apoptosis 
is triggered. The highest concentrations 
used are too low to induce excessive DNA 
damage that would lead to rapid cell death. 
However, DNA damage seems sufficient to 
activate executioner caspases and apopto-
sis.
After electrochemotherapy with CDDP, 
cell viability was significantly reduced 
at 266.6 µM and significant caspase-3/7 
fold induction was seen at 133.3 µM and 
266.6 µM. This indicates that apoptosis 
is triggered at these high concentrations. 
Similarly to BLM, at low CDDP concentra-
tions, cells were metabolically active and 
caspase-3/7 fold induction was not signifi-
cantly increased. Also, it was previously 
demonstrated that at low CDDP concen-
trations (8 µM) cells die of apoptotic death 
over several days.22 In our experiments, cas-
pase-3/7 activity was measured 16 hours af-
ter electrochemotherapy, which is too short 
a time to induce enough DNA damage to in-
duce apoptosis at these low concentrations.
Although caspase-3/7 activation was 
significant at high concentrations, not all 
cells underwent apoptosis. Morphological 
changes observed after treatment with 
BLM or CDDP or electrochemotherapy 
with BLM or CDDP were the presence of 
apoptotic bodies, piknosis, karyorrhexis, 
and karyolysis. On the one hand, apoptotic 
bodies, piknosis and karyorrhexis are hall-
marks of apoptosis, whereas on the other 
hand, karyolysis is typical for necrotic cells. 
Our results demonstrated that cells died of 
either apoptotic or necrotic cell death after 
electrochemotherapy with BLM or CDDP. 
Necrotic cells were more abundant at high-
er BLM or CDDP concentrations, especially 
after electrochemotherapy. These results 
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are in agreement with cell viability and the 
caspase-3/7 activity assay. However, re-
duced cell viability at high BLM or CDDP 
concentrations after electrochemotherapy 
was not only due to apoptosis, but also due 
to necrosis which resulted in pronounced 
reduction of the cell’s clonogenic potential.
To conclude, our study confirmed that 
CMT-93 colorectal carcinoma cells are sen-
sitive to electrochemotherapy with both 
BLM and CDDP. To apply electrochemo-
therapy to the treatment of colorectal car-
cinoma, special electrodes that allow deliv-
ery of electric pulses to more deep-seated 
tumours must be developed. Currently, 
electrode systems are under development 
for intra-luminal delivery by endoscopes, 
laparoscopic systems or intravascular cath-
eters.26 Further development of special 
electrodes will permit application of elec-
trochemotherapy to the treatment of color-
ectal carcinoma for those patients that can-
not undergo traditional treatment modali-
ties due to severe complications.
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